Related Experiment Video

Updated: Jun 10, 2026

Generating Genetically Modified Plasmodium berghei Sporozoites
10:16

Generating Genetically Modified Plasmodium berghei Sporozoites

Published on: May 5, 2023

Microsporidiosis: epidemiology, clinical data and therapy

S Anane1, H Attouchi

  • 1Laboratoire de parasitologie-mycologie, faculté de médecine, Tunis, Tunisia.

Gastroenterologie Clinique Et Biologique
|August 13, 2010
PubMed

Insights

Microsporidiosis, an opportunistic infection caused by fungi, affects immunocompromised individuals. While albendazole treats some species, new drugs are needed for Enterocytozoon bieneusi infections.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Parasitology

Background:

  • Microsporidiosis is an emerging opportunistic infection in immunocompromised individuals and other populations.
  • Caused by microsporidia, now classified as fungi, these obligate intracellular microorganisms lead to diverse clinical syndromes.
  • Enterocytozoon bieneusi and Encephalitozoon intestinalis are the most common human pathogens, causing diarrhea and systemic illness.

Purpose of the Study:

  • To review the current understanding of microsporidiosis, including its causative agents, transmission routes, and clinical manifestations.
  • To evaluate the efficacy and limitations of existing therapeutic agents for human microsporidiosis.
  • To highlight the need for novel, safe, and effective treatments.

Main Methods:

  • Literature review of microsporidiosis, focusing on epidemiology, clinical features, and treatment options.
  • Analysis of drug efficacy data for albendazole, fumagillin, and TNP 470 against different microsporidia species.
  • Identification of knowledge gaps in the treatment of human microsporidiosis.

Main Results:

  • Albendazole is effective against Encephalitozoon species but not Enterocytozoon bieneusi.
  • Fumagillin shows efficacy against Enterocytozoon bieneusi but has systemic toxicity.
  • TNP 470, a fumagillin analog, presents a potential alternative, though further research is required.

Conclusions:

  • Current treatments for microsporidiosis have variable success and limitations.
  • There is a critical need for the development of new drugs that are both effective and safe for treating Enterocytozoon bieneusi infections.
  • Continued research is essential to identify and validate novel therapeutic strategies for microsporidiosis.

More Related Videos

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Related Concept Videos

Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Toxoplasmosis01:28

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...